Download PDF
Thromb Haemost 2004; 92(02): 229-231
DOI: 10.1160/TH04-05-0305
Editorial Focus
Schattauer GmbH

Clopidogrel “resistance”

Karsten Schrör
1   Institut für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
,
Artur Aron Weber
1   Institut für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
,
Thomas Hohlfeld
1   Institut für Pharmakologie und Klinische Pharmakologie, Heinrich-Heine-Universität Düsseldorf, Düsseldorf, Germany
› Author Affiliations
Further Information

Publication History

Received 17 May 2004

Accepted 25 May 2004

Publication Date:
30 November 2017 (online)

Also available at
    Permissions and Reprints

 

 

  • References

  • 1 Roses S, Galaxo Chief. Our drugs do not work on most patients. In an interview with Steve Connor, Science Editor; Independent. UK: December 08; 2003
    Search in Google Scholar
  • 2 Mukherjee D, Topol EJ. Pharmacogenomics in cardiovascular diseases. Progr Cardiovasc Dis 2002; 44: 479-498.
    CrossrefPubMedSearch in Google Scholar
  • 3 Antithrombotic Trialists’ Collaboration. Collaborative metaanalysis of randomized trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high-risk patients. Br Med J 2002; 324: 71-86.
    CrossrefPubMedSearch in Google Scholar
  • 4 Holmes MB, Sobel BE, Schneider DJ. Variable responses to inhibition of fibrinogen binding induced by tirofiban and eptifibatide in blood from healthy subjects. Am J Cardiol 1999; 84: 203-207.
    CrossrefPubMedSearch in Google Scholar
  • 5 Zimmermann N, Wenk A, Kim U. et al. Functional and biochemical evaluation of platelet aspirin resistance after coronary artery bypass surgery. Circulation 2003; 108: 542-547.
    CrossrefPubMedSearch in Google Scholar
  • 6 Weber A-A, Przytulski B, Schanz A. et al. Towards a definition of aspirin resistance: a typological approach. Platelets 2002; 13: 37-40.
    CrossrefPubMedSearch in Google Scholar
  • 7 Gurbel PA, Bliden KP, Hiatt BL. et al. Clopidogrel for coronary stenting. Response variability, drug resistance, and the effect of pretreatment platelet reactivity. Circulation 2003; 107: 2908-2913.
    PubMedSearch in Google Scholar
  • 8 Müller I, Besta F, Schulz C. et al. Prevalence of clopidogrel non-responders among patients with stable angina pectoris scheduled for elective coronary stent placement. Thromb Haemost 2003; 89: 783-787.
    Thieme ConnectPubMedSearch in Google Scholar
  • 9 Bachmann F, Savcic M, Hauert J. et al. Rapid onset of inhibition of ADP-induced platelet aggregation by a loading dose of clopidogrel. Eur Heart J 1996; 17 (Suppl) 263.
    PubMedSearch in Google Scholar
  • 10 Gawaz M, Seyfarth M, Müller I. et al. Comparison of the effects of clopidogrel versus ticlopidine on platelet function in patients undergoing coronary stent placement. Am J Cardiol 2001; 87: 332-336.
    CrossrefPubMedSearch in Google Scholar
  • 11 Müller I, Seyfarth M, Rüdiger S. et al. Effect of a high loading dose of clopidogrel on platelet function in patients undergoing coronary stent placement. Heart 2001; 85: 92-93.
    CrossrefPubMedSearch in Google Scholar
  • 12 Steinhubl SR, Berger PB, Mann 3rd JT. et al. CREDO investigators. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002; 288: 2411-2420.
    PubMedSearch in Google Scholar
  • 13 Kastrati A, Mehilli J, Schuhlen H. et al. Intracoronary stenting and antithrombotic regimen rapid early action for coronary treatment study investigators. N Engl J Med 2004; 350: 232-238.
    CrossrefPubMedSearch in Google Scholar
  • 14 Hochholzer W, Trenk D, Frundi D. et al. Ausmaß der Thrombozyteninhibition nach einer Initialdosis von 600 mg Clopidogrel und Prävalenz von Non-Respondern zum Zeitpunkt der Koronarintervention. Z Kardiol 2004; 93 (Suppl. 03) 392.
    PubMedSearch in Google Scholar
  • 15 McKee SA, Sane DC, Deliargyris EN. Aspirin resistance in cardiovascular disease: A review of prevalence, mechanisms and clinical significance. Thromb Haemost 2002; 88: 711-715.
    Thieme ConnectPubMedSearch in Google Scholar
  • 16 Lau WC, Gurbel PA, Watkins PB. et al. Contribution of hepatic cytochrome P450 3A4 metabolic activity to the phenomenon of clopidorel resistance. Circulation 2004; 109: r1-r6.
    CrossrefPubMedSearch in Google Scholar
  • 17 Taubert D, Kastrati A, Harlfinger S. et al. Pharmacokinetics of clopidogrel after administration of a high loading dose. Thromb Haemost 2004; 92: 311-316.
    Thieme ConnectPubMedSearch in Google Scholar
  • 18 Bretschneider E, Glusa E, Schrör K. ADP-, PAF- and adrenaline-induced platelet aggregation and thromboxane formation are not affected by a thromboxane receptor antagonist at physiological Ca++-levels. Thromb Res 1994; 75: 233-242.
    CrossrefPubMedSearch in Google Scholar
  • 19 Weber A-A, Meila D, Jacobs C. et al. Low incidence of paradoxical platelet activation by glycoprotein IIb/IIIa inhibitors. Thromb Res 2002; 106: 25-29.
    CrossrefPubMedSearch in Google Scholar
  • 20 Soffer D, Moussa I, Harjai KJ. et al. Impact of anginal class on inhibition of platelet aggregation following clopidogrel loading in patients undergoing coronary intervention: Do we need more aggressive dosing regimens in unstable angina?. Cathet Cardiovasc Intervent 2003; 59: 21-25.
    CrossrefPubMedSearch in Google Scholar